Claims

[Claim 1] Use of an anti-OX40 antibody in the manufacture of a composition for the treatment of an OX40-related immune- or allergy-related disease, wherein the anti-OX40 antibody is to be subcutaneously administered to a patient at a dose of 150 mg to 600 mg once in two weeks to four weeks for at least 16 weeks.

[Claim 2] The use according to claim 1, wherein the anti-OX40 antibody is a monoclonal antibody containing a heavy chain variable region (also called VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (also called VL) containing the amino acid sequence of SEQ ID NO: 2.

[Claim 3] The use according to claim 1 or 2, wherein the administration is to be continued for at least 20 weeks, 22 weeks, 24 weeks or 34 weeks after starting the administration.

[Claim 4] The use according to claim 1, wherein the OX40-related immune- or allergy-related disease is atopic dermatitis.

[Claim 5] The use according to any of claims 1-4, wherein the anti-OX40 antibody is to be subcutaneously administered once in two weeks, three weeks or four weeks.

[Claim 6] The use according to any of claims 1-5, wherein the dose is selected from 150 mg, 300 mg, 450 mg and 600 mg.

[Claim 7] The use according to any of claim 1, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis.

[Claim 8] The use according to claim 1, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis which is poorly controllable using a topical agent or moderate to severe atopic dermatitis for which a topical therapy is not medically recommended.

[Claim 9] The use according to any of claims 1-8 which is combined with a known topical agent such as a steroid.

[Claim 10] The use according to any of claims 1-9, wherein the anti-OX40 antibody is KHK4083.

[Claim 11] Use of an anti-OX40 antibody in the manufacture of a medicament for the treatments of an OX40-related immune- or allergy-related disease, wherein an anti-OX40 antibody is to be subcutaneously administered to a patient at a dose of 150 mg to 600 mg once in two weeks to four weeks continuously

at the same dose.

[Claim 12] The use according to claim 11, wherein the anti-OX40 antibody is a monoclonal antibody containing a heavy chain variable region (also called VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (also called VL) containing the amino acid sequence of SEQ ID NO: 2.

[Claim 13] The use according to claim 11 or 12, wherein the administration is to be continued for at least 16 weeks, 20 weeks, 22 weeks, 24 weeks or 34 weeks after starting the administration.

[Claim 14] The use according to any of claims 11-13, wherein the OX40-related immune- or allergy-related disease is atopic dermatitis.

[Claim 15] The use according to any of claims 11-14, wherein the anti-OX40 antibody is to be subcutaneously administered once in two weeks, three weeks or four weeks.

[Claim 16] The use according to any of claims 11-15, wherein the dose is selected from 150 mg, 300 mg, 450 mg and 600 mg.

[Claim 17] The use according to any of claims 11-16, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis.

[Claim 18] The use according to any of claims 11-17, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis which is poorly controllable using a topical agent or moderate to severe atopic dermatitis for which a topical therapy is not medically recommended.

[Claim 19] The use according to any of claims 11-18, which is combined with a known topical agent such as a steroid.

[Claim 20] The use according to any of claims 11-19, wherein the anti-OX40 antibody is KHK4083.